Aprea Therapeutics (NASDAQ:APRE) Stock, Quote.Headers.trade-ideas

Aprea Therapeutics

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

pharma lab worker ai

Biotech

Equities

News

Financing

Movers

Trading Ideas

General

APRE

FDA clearance for Aprea Therapeutics&#39; APR-1051 IND application, a promising WEE1 kinase inhibitor. Phase 1 trial initiation in 2024, focusing on Cyclin E cancers. $34 million private placement to fund clinical development and ensure company sustainability until 2026.

Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?

Long Ideas

Penny Stocks

Small Cap

Insider Trades

Pre-Market Outlook

Markets

ERAS

STSA

The Dow Jones closed higher by over 160 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying

Offerings

Aprea Therapeutics Inc (NASDAQ: APRE) shares are trading lower by 17.59% to $5.20 after the company announced pricing of a $5.5 million underwritten public offering of common stock.

What Else?

Why Aprea Therapeutics Shares Hit A New 52-Week Low Today

Aprea Therapeutics Inc

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AstraZeneca (AZN – Research Report) and Aprea Therap...

Analysts' Top Healthcare Picks: AstraZeneca (AZN), Aprea Therapeutics (APRE)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mirum Pharmaceuticals (MIRM – Research Report), Goss...

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), Gossamer Bio (GOSS) and Aprea Therapeutics (APRE)

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Aprea Therapeutics (APRE – Research Report), retaining the price target of $16.00....

Aprea Therapeutics' APR-1051: Poised for Leadership in WEE1 Inhibition with Promising Clinical and Market Potential

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Aprea Therapeutics (APRE – Research Report), with a pr...

Buy Rating Affirmed for Aprea Therapeutics on APR-1051's Promising Safety and Efficacy Profile

Maxim Group analyst Jason McCarthy has maintained their bullish stance on APRE stock, giving a Buy rating on June 24. Jason McCarthy has given his ...

Buy Rating on Aprea Therapeutics: Outshining Competitors with Selective and Potent WEE1 Inhibitor APR-1051

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aprea Therapeutics (APRE – Research Report) and TSca...

Analysts Are Bullish on These Healthcare Stocks: Aprea Therapeutics (APRE), TScan Therapeutics (TCRX)

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Aprea Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/apre-stock-quote/"><strong>APRE</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Aprea Therapeutics reported earnings per share of -58 cents. This was above the analyst estimate for EPS of -64 cents.</li><li>The company reported revenue of $561,574.</li><li>This was 1,023.15% better than the analyst estimate for revenue of $50,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/apre-stock-earnings-aprea-therapeutics-for-q2-of-2024/">APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024

Aprea Therapeutics GAAP EPS of -$0.58, revenue of $561.57M

In a report released today, Robert Driscoll from Wedbush initiated coverage with a Buy rating on Aprea Therapeutics (APRE – Research Report) and a ...

Wedbush Initiates a Buy Rating on Aprea Therapeutics (APRE)

Maxim Group analyst Jason McCarthy reiterated a Buy rating on Aprea Therapeutics (APRE – Research Report) yesterday and set a price target of $16.0...

Buy Rating Justified by Aprea Therapeutics' Financial Health and Innovative Clinical Trials

GOSS

MIRM

TCRX

Health Care

Press Releases

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Aprea Therapeutics

Aprea Therapeutics (APRE) Forecast

Aprea Therapeutics (NASDAQ:APRE) Stock, Quote.Headers.trade-ideas